Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Saturday, May 24, 2025

Use and Eligibility for Glucose-Like Peptide-1 Receptor Agonist Treatment for Primary Prevention of Stroke

 You're living in la-la land if you think this has become a protocol at your stroke hospital. Ask the question, and not politely. So far 1 year to accomplish this. Is your hospital a failure?

Use and Eligibility for Glucose-Like Peptide-1 Receptor Agonist Treatment for Primary Prevention of Stroke

. 2025 Jun 24;104(12):e213739.
doi: 10.1212/WNL.0000000000213739. Epub 2025 May 23.       

Linnea M Wilson  1 , Timothy S Anderson  2   3   4
Affiliations

Abstract

Objectives: The 2024 American Heart Association and American Stroke Association stroke prevention guideline newly recommended glucose-like peptide-1 receptor agonists (GLP-1s) for primary prevention of stroke in patients with diabetes and elevated risk of atherosclerotic cardiovascular disease (ASCVD). We aimed to characterize the population newly recommended GLP-1s.

Methods: This cross-sectional study included adults aged 30-79 years without previous stroke and with diabetes who participated in the National Health and Nutrition Examination Survey from 2017 to March 2020. Participants were guideline-eligible for GLP-1 if they had HbA1C ≥7% and existing or a high 10-year risk of ASCVD. Current GLP-1 users were identified by in-home review of medications. Data were weighted to be nationally representative.

Results: The study included 1,104 participants (mean age 60 years; 45% female) representing 23.5 million (95% CI, 21.2 million-25.8 million) US adults with diabetes. Stroke prevention guideline recommendations would apply to 4.9 million (95% CI, 3.7 million-6.0 million) US adults. GLP-1 eligibility was more common among older adults, men, and those with private insurance or Medicare. Only 6.8% (95% CI 3.3%-10.7%) of adults meeting recommendations were taking a GLP-1.

Discussion: Almost 5 million Americans with diabetes would qualify for GLP-1 use for primary prevention of stroke, but current use among this population is very low.     

Posted by at
Labels: , , , ,

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)